Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2017

Published: Jul, 2017 | Pages: 446 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2017, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape.

Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 28, 27, 3, 75, 28 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 7
Non-Alcoholic Steatohepatitis (NASH) - Overview 8
Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Development 9
Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Assessment 29
Non-Alcoholic Steatohepatitis (NASH) - Companies Involved in Therapeutics Development 45
Non-Alcoholic Steatohepatitis (NASH) - Drug Profiles 91
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects 413
Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products 416
Non-Alcoholic Steatohepatitis (NASH) - Product Development Milestones 417
Appendix 428

List of Tables

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Products under Development by Companies, H2 2017 (Contd..7), H2 2017
Products under Development by Companies, H2 2017 (Contd..8), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AdAlta Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Albireo Pharma Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Allergan Plc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Alnylam Pharmaceuticals Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Amunix Operating Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Aquinox Pharmaceuticals Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Arcturus Therapeutics Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ardelyx Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AstraZeneca Plc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Betagenon AB, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by BioLineRx Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Bird Rock Bio Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by BLR Bio LLC, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Bristol-Myers Squibb Company, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Can-Fite BioPharma Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Cardax Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Carmot Therapeutics Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Catabasis Pharmaceuticals Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Cerenis Therapeutics Holding SA, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ChemoCentryx Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by CohBar Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Conatus Pharmaceuticals Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Connexios Life Sciences Pvt Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ConSynance Therapeutics Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by CymaBay Therapeutics Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dimerix Bioscience Pty Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by DURECT Corp, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dynavax Technologies Corp, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Eli Lilly and Company, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Enanta Pharmaceuticals Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Exicure Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Foresee Pharmaceuticals LLC, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Forma Therapeutics Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galectin Therapeutics Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galmed Pharmaceuticals Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Gemphire Therapeutics Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Genfit SA, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by GenKyoTex SA, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Gilead Sciences Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by GlaxoSmithKline Plc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by GRI Bio Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by iCo Therapeutics Inc., H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Immuron Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Intercept Pharmaceuticals Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Inventiva, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Matinas BioPharma Holdings Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by MedImmune LLC, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Merck & Co Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Metacrine Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Mitochon Pharmaceuticals Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Naia Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by NeuroVive Pharmaceutical AB, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by NGM Biopharmaceuticals Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Nippon Chemiphar Co Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Nordic Bioscience A/S, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Novartis AG, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by NovaTarg Therapeutics Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Novo Nordisk A/S, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Nuevolution AB, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ocera Therapeutics Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Pfizer Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Pharmaxis Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Promethera Biosciences SA, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ProMetic Life Sciences Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Protalix BioTherapeutics Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Redx Pharma Plc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Regulus Therapeutics Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Saje Pharma LLC, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Sancilio & Company Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Seres Therapeutics Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Shire Plc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Sprint Bioscience AB, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Synlogic Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Tiziana Life Sciences Plc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by TRACON Pharmaceuticals Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Translate Bio Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Vascular Biogenics Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Verlyx Pharma Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Viking Therapeutics Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Virobay Inc, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Zydus Cadila Healthcare Ltd, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, H2 2017 (Contd..1), H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, H2 2017 (Contd..2), H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products, H2 2017